Fortis Capital Advisors LLC acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,700 shares of the company's stock, valued at approximately $703,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Hurley Capital LLC bought a new stake in IDEXX Laboratories in the fourth quarter valued at $29,000. Rialto Wealth Management LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $30,000. Retirement Wealth Solutions LLC acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $31,000. Kestra Investment Management LLC bought a new position in IDEXX Laboratories during the 4th quarter valued at about $38,000. Finally, Crews Bank & Trust acquired a new position in IDEXX Laboratories in the fourth quarter valued at about $41,000. 87.84% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of research firms have recently issued reports on IDXX. Bank of America lifted their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Barclays boosted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research report on Monday. Finally, Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $523.75.
Get Our Latest Analysis on IDEXX Laboratories
IDEXX Laboratories Trading Down 0.2 %
IDEXX Laboratories stock traded down $0.63 during trading hours on Tuesday, reaching $404.02. 985,075 shares of the company's stock traded hands, compared to its average volume of 619,975. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $548.88. The firm's 50 day moving average is $426.75 and its 200-day moving average is $432.85. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The firm has a market capitalization of $32.74 billion, a price-to-earnings ratio of 37.87, a PEG ratio of 3.41 and a beta of 1.50.
Insider Activity at IDEXX Laboratories
In related news, EVP George Fennell sold 9,986 shares of the company's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.
IDEXX Laboratories Profile
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
See Also
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
